Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature.

R Heregger, Florian Huemer (Co-author), Georg Hutarew (Co-author), Stefan Hecht (Co-author), L Cheveresan, Dieter Kotzot (Co-author), E Schamschula, Gabriel Rinnerthaler (Co-author), Thomas Melchardt (Co-author), Lukas Weiss (Last author), Richard Greil* (Last author)

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Citations (Web of Science)
Original languageEnglish
Pages (from-to)100233
JournalESMO OPEN
Volume6
Issue number4
DOIs
Publication statusPublished - 2021

Keywords

  • MALIGNANT PHEOCHROMOCYTOMA
  • LUNG-CANCER
  • ALK
  • PARAGANGLIOMA
  • NEUROBLASTOMA
  • CRIZOTINIB
  • ALECTINIB
  • CYCLOPHOSPHAMIDE
  • VINCRISTINE
  • GENETICS

Cite this